Q00987 (MDM2_HUMAN) Homo sapiens (Human)

E3 ubiquitin-protein ligase Mdm2 UniProtKBInterProSTRINGInteractive Modelling

491 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5; Isoform 6; Isoform 7; Isoform 8; Isoform 9; Isoform 10; Isoform 11; )

Sequence Features

Add
 299-328RanBP2-type
 438-479RING-type
 29-95SWIB/MDM2 domain
IPR003121PF02201
 300-327Zinc finger, RanBP2-type
IPR001876PF00641

Sequence Alignments

Experimental structures

DescriptionOligo-stateLigandsStructureRange
Structure of complex of MDM2(3-109) and P73 TAD(10-25) Heteromer
O15350;
2mps3-109
Assess
Green fluorescent protein linked MTide-02 inhibitor in complex with mdm2 Heteromer
GOL;PO4;PG4;5wts15-110
Assess
MDM2 bound CueO-PM2 sensor Heteromer
P36649;
6im925-111
Assess
Crystal structure of p53 epitope-scaffold based on a inhibitor of cysteine proteases in complex wit… Heteromer
CL;SO4;GOL;5swk26-110
Assess
MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 Heteromer
P04637;
1ycr25-109
Assess
Crystal structure of human MDM2 in complex with a potent miniature protein inhibitor (18-residues) Heteromer
ACT;CL;3iux27-109
Assess
Crystal Structure of an MDM2/P53 Peptide Complex Heteromer
P04637;
SO4;4hfz26-108
Assess
Solution structure of Hdm2 with engineered cyclotide Heteromer
2m8627-109
Assess
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Heteromer
O15151;
ZN;2vjf428-491
Assess
Structure of MDM2-MDMX-UbcH5B-ubiquitin complex Heteromer
O15151; P0CG47; P62837;
ZN;SO4;5mnj429-491
Assess
Crystal structure of human MDM2 RING domain homodimer bound to UbcH5B-Ub Heteromer
P62837; P62979;
ZN;CL;NO3;6sqo430-491
Assess
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Heteromer
O15151;
ZN;2vje432-491
Assess
Crystal structure of human MDM2-RPL11 Heteromer
P62913;
IMD;BME;ZN;4xxb293-334
Assess
Crystal Structure of the USP7:Hdm2(PSTS) complex Heteromer
Q93009;
3mqs395-401
Assess
The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150 Heteromer
Q93009;
2fop145-150
Assess
CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITORhomo-3-mer IMZ;1rv125-109
Assess
Ordering of the N Terminus of Human MDM2 by Small Molecule Inhibitorshomo-2-mer 0Y7;4hbm6-111
Assess
MDM2 in complex with SAR405838homo-2-mer 7HC;SO4;GOL;5trf10-111
Assess
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.homo-2-mer 6GG;5j7f11-111
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidinehomo-2-mer 62T;SO4;5hmi18-116
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidinehomo-2-mer 62R;SO4;5hmh21-116
Assess
Structure of Human MDM2 in complex with a Benzodiazepine Inhibitorhomo-2-mer DIZ;1t4e16-111
Assess
Structure of a stapled peptide antagonist bound to Nutlin-resistant Mdm2.homo-2-mer 4umn18-112
Assess
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.homo-2-mer 6GG;5j7g18-111
Assess
X-ray structure of the p53-MDM2 inhibitor NMI801 bound to HDM2 at 2.1A resolutionhomo-2-mer H0W;6i2919-111
Assess
HDM2 in complex with a beta-hairpinhomo-2-mer SO4;MPO;2axi23-114
Assess
Crystal Structure of an MDM2/Nutlin-3a complexhomo-2-mer NUT;SO4;4hg718-108
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidinehomo-2-mer 62Q;5hmk21-111
Assess
Structure of the Stapled p53 Peptide Bound to Mdm2homo-2-mer CL;3v3b24-110
Assess
Crystal structure of human MDM2 with a 12-mer peptide inhibitor PMI (N8A mutant)homo-2-mer CL;3lnz25-109
Assess
Structure of human MDM2 protein in complex with a small molecule inhibitorhomo-2-mer K23;SO4;3lbk26-110
Assess
Structure of hDM2 with Dimer Inducing Indolyl Hydantoin RO-2443homo-2-mer 03M;3vbg25-109
Assess
Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitorhomo-2-mer GAI;3eqs26-109
Assess
Crystal structure of human MDM2 in complex with D-peptide inhibitor (DPMI-alpha)homo-2-mer SO4;CL;3lnj26-108
Assess
Solution Structure of Hdm2 RING Finger Domainhomo-2-mer ZN;2hdp429-491
Assess
NMR Structure of Mdm2 (6-125) with Pip-1monomer 13Q;2lzg1-125
Assess
NMR structure of unliganded MDM2monomer 1z1m1-118
Assess
Co-crystal Structure of MDM2 in Complex with AM-7209monomer 3UD;SO4;4wt26-110
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 4monomer 2U0;SO4;4ode6-110
Assess
Co-Crystal Structure of MDM2 with Inhbitor Compound 3monomer 2U5;SO4;4ogn11-110
Assess
Co-Crystal Structure of MDM2 with Inhbitor Compound 46monomer 2U6;SO4;4ogt12-110
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 47monomer 2U1;4odf12-110
Assess
Chemical Shift Assignments for MIP and MDM2 in bound statemonomer 2ruh6-102
Assess
Structure of the stapled peptide YS-01 bound to MDM2monomer 4ue117-112
Assess
Structure of the stapled peptide YS-02 bound to MDM2monomer 4ud717-112
Assess
Structure of MDM2 with low molecular weight inhibitormonomer B5K;5oai18-113
Assess
Human MDM2 liganded with a 12mer peptide inhibitor (pDI6W)monomer 3jzr17-112
Assess
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-bas…monomer 6ZT;SO4;CL;5ln217-111
Assess
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acidsmonomer 5xxk18-112
Assess
Structure of Mdm2 with low molecular weight inhibitormonomer 4NJ;4zfi18-112
Assess
Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of t…monomer GOL;SO4;6SS;5lay17-111
Assess
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 9 AT 1.13A; Structural states of Hdm2 and HdmX: X-r…monomer HTZ;CL;6q9l18-111
Assess
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-…monomer HU8;6q9o17-110
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer 6SJ;SO4;5law18-111
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer 6ST;ZN;SO4;5laz18-111
Assess
Crystal structure of MDM2 in complex with compound 13.monomer H28;GOL;SO4;6i3s18-111
Assess
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitormonomer EYH;CL;6ggn18-111
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56Amonomer 9QW;CL;5oc819-111
Assess
Structure of human MDM2 protein in complex with Mi-63-analogmonomer MI6;3lbl18-110
Assess
Exhaustive Fluorine Scanning towards Potent p53-MDM2 Antagonistmonomer 07G;3tu118-110
Assess
Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro…monomer 1MT;4jvr18-110
Assess
co-crystal structure of MDM2 (17-111) with compound 16, {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP…monomer 35S;4qo418-110
Assess
co-crystal structure of MDM2 (17-111) in complex with compound 25monomer 2SW;4oas18-110
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer 6SK;SO4;5lav19-111
Assess
co-crystal structure of MDM2(17-111) in complex with compound 48monomer 2TZ;4occ18-110
Assess
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical …monomer 4T4;CL;4zyf18-110
Assess
The Central Valine Concept Provides an Entry in a New Class of Non Peptide Inhibitors of the P53-MD…monomer BLF;4dij18-110
Assess
Structure of a novel submicromolar MDM2 inhibitormonomer Y30;SO4;4mdn18-110
Assess
Structure of Mdm2 with low molecular weight inhibitor.monomer 4NX;4zgk18-110
Assess
crystal structure of MDM2 with chromenotriazolopyrimidine 1monomer YIN;3jzk18-110
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 49monomer 2U7;4ogv18-110
Assess
Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interactionmonomer 2V8;4oq318-110
Assess
Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluo…monomer 1MQ;4jve18-110
Assess
Crystal Structure of HDM2 in complex with Nutlin-3amonomer NUT;SO4;CL;IOD;5c5a20-111
Assess
Co-crystal structure of MDM2 with Inhibitor Compound 4monomer 2TW;4oba19-110
Assess
Structure of a stapled peptide bound to MDM2monomer O9E;6y4q17-108
Assess
crystal structure of compound 16 bound to MDM2(17-111), {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP…monomer 35T;4qoc19-110
Assess
crystal structure of MDM2 (17-111) in complex with compound 29 (AM-8553)monomer 0R3;4erf19-110
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 11 AT 2.0A; Structural states of Hdm2 and HdmX: X-…monomer HRH;6q9h19-110
Assess
Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2…monomer 1MY;4jwr19-110
Assess
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical …monomer 4TH;CL;4zyi20-110
Assess
Crystal structure of Mdm2 bound to a stapled peptidemonomer FL5;6h2218-108
Assess
crystal structure of MDM2 (17-111) in complex with compound 23monomer 0R2;SO4;4ere22-111
Assess
X-ray structure of Mdm2 with modified p53 peptidemonomer 7ad024-113
Assess
Structure of a novel submicromolar MDM2 inhibitormonomer TJ2;K;3tj221-110
Assess
Crystal structure of HIS6-tagged Mdm2 with nutlin-3amonomer NUT;5z0224-111
Assess
MDM2 in complex with an 8-mer p53 peptide analoguemonomer 2gv225-112
Assess
Structure of human MDM2 in complex with an optimized p53 peptidemonomer SO4;1t4f23-110
Assess
The 1.25A Crystal structure of His6-tagged Mdm2 in complex with nutlin-3amonomer NUT;5zxf24-110
Assess
Crystal structure of hDM2 in complex with a C-terminal triurea capped peptide chimera foldamer.monomer UCV;6hfa25-111
Assess
Structure of human MDM2 in complex with high affinity peptidemonomer 3g0325-111
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 12 AT 1.8A; Structural states of Hdm2 and HdmX: X-…monomer HRE;SO4;6q9625-111
Assess
Mdm2 in complex with a D amino Acid Containing Stapled Peptidemonomer 6aaw26-111
Assess
Structure of a novel submicromolar MDM2 inhibitormonomer 28W;4mdq25-110
Assess
Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity:…monomer 6kzu25-109
Assess
Crystal structure of human MDM2 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate…monomer CL;5vk025-109
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomer EPE;DMS;M9E;6t2d25-109
Assess
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitormonomer LTZ;SO4;3w6925-109
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomer M9H;6t2f25-109
Assess
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorp…monomer 1MN;SO4;4jv726-110
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomer 6t2e25-109
Assess
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmor…monomer 1MO;SO4;4jv926-110
Assess
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitormonomer VZV;3vzv25-109
Assess
Crystal structure of human MDM2 in complex with a trifluoromethylated D-peptide inhibitormonomer SO4;3tpx26-109
Assess
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with…monomer 4SS;4zyc25-108
Assess
Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ)monomer EDO;3jzs26-108
Assess
Structure of the Stapled Peptide Bound to Mdm2monomer P07;5afg26-108
Assess
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3monomer CL;5umm27-108
Assess
Crystal structure of human MDM2 complexed with D-peptide (12 residues)monomer 3iwy26-107
Assess
Solution structure of the C4 zinc-finger domain of HDM2monomer ZN;2c6a290-335
Assess
Solution structure of the C4 zinc-finger domain of HDM2monomer ZN;2c6b290-335
Assess

Homology models built on isoform sequence

IsoformOligo-stateLigandsQMEANTemplateRangeSeq id (%)
Isoform 2monomerZN;-0.926sqp.1.A235-296
95.16
Assess
Isoform 2monomerZN;-0.554xxb.1.B98-139
100.00
Assess
Isoform 2monomer-3.801z1m.1.A1-27
100.00
Assess
Isoform 3monomerZN;-1.296sqs.1.A208-270
95.24
Assess
Isoform 3monomerZN;-0.684xxb.1.B77-113
97.78
Assess
Isoform 3monomer-3.941z1m.1.A1-27
100.00
Assess
Isoform 4monomerZN;-0.915mnj.1.C156-218
100.00
Assess
Isoform 4monomerZN;-0.934xxb.1.B22-61
96.38
Assess
Isoform 5homo-2-merZN;-2.712hdp.1.A259-321
100.00
Assess
Isoform 5monomer-2.112lzg.1.A1-58
91.38
Assess
Isoform 5monomer-4.771z1m.1.A1-58
91.38
Assess
Isoform 5monomerZN;-0.554xxb.1.B123-164
100.00
Assess
Isoform 6monomerZN;-0.915mnj.1.C70-132
100.00
Assess
Isoform 6monomer-4.361z1m.1.A1-37
78.38
Assess
Isoform 6monomer-2.152lzg.1.A1-37
78.38
Assess
Isoform 7monomer-1.815j7f.1.B12-93
84.95
Assess
Isoform 8monomerZN;-0.745mnj.1.C372-430
100.00
Assess
Isoform 8monomer-0.982axi.1.A1-53
100.00
Assess
Isoform 8monomerZN;-0.554xxb.1.B232-273
100.00
Assess
Isoform 9monomerZN;-0.745mnj.1.C388-446
100.00
Assess
Isoform 9monomer-1.264hbm.1.A6-66
100.00
Assess
Isoform 9monomerZN;-0.554xxb.1.B248-289
100.00
Assess
Isoform 9monomer-3.532mps.1.A3-100
64.29
Assess
Isoform 9monomer-4.972ruh.1.A6-100
62.96
Assess
Isoform 10monomer-0.615j7f.1.A11-111
100.00
Assess
Isoform 10monomerZN;-0.745mnj.1.C378-436
100.00
Assess
Isoform 10monomerZN;-0.554xxb.1.B238-279
100.00
Assess
Isoform 11homo-2-mer6GG;-0.645j7f.1.A17-117
100.00
Assess
Isoform 11monomerZN;-0.745mnj.1.C439-497
100.00
Assess
Isoform 11monomerZN;-0.554xxb.1.B299-340
100.00
Assess